Increasing ultraviolet light exposure is associated with reduced mortality from *Clostridium difficile* infection

Shail M Govani¹, Akbar K Waljee^{1,2}, Ryan W Stidham¹ and Peter DR Higgins¹

Abstract

Background: *Clostridium difficile* infection (CDI) is an increasingly common cause of inpatient mortality. Vitamin D deficiency is associated with more aggressive CDI. We aimed to determine if average annual ultraviolet light (UV) exposure was associated with mortality in patients with CDI.

Methods: We used the US National Inpatient Sample (NIS) from 2004–2011 to assess the mortality risk in patients with a diagnosis of CDI (as per ICD-9CM 008.45). Annual average state UV exposure was assigned to each hospitalization. Logistic regression was used to determine the effects of UV exposure on mortality, controlling for age, gender, race and other comorbidities.

Results: During the study period, there were 2.61 million hospitalizations with a diagnosis of CDI. The mortality rate was 9.0%. In univariate analysis, the odds ratio (OR) of inpatient mortality for the UV index was 0.97 (95% CI 0.95–0.99; $p=0.008$) per unit of UV exposure. In a multivariable model adjusting for age, gender, race, Charlson-Deyo index, season and coexisting inflammatory bowel disease, the UV index remained a protective predictor, with an OR of 0.94 (95% CI 0.92–0.96; $p<0.001$). In the multivariate model, a seasonal effect was also present, with the highest risk of inpatient mortality in the period from January to March (OR 1.11; 95% CI 1.08–1.14) and the lowest risk, from July to September (OR 0.95; 95% CI 0.92–0.98).

Conclusions: An increase in UV exposure index is associated with a reduced risk of inpatient mortality in patients with CDI. A seasonal effect is also present, with the highest risk of death during winter months. Further studies exploring the role of UV light in CDI are necessary.

Keywords

Clostridium difficile, colitis, infectious disease, mortality, risk factors, seasonality, ultraviolet light, vitamin D

Received: 22 September 2014; accepted: 9 December 2014

Background

Clostridium difficile infection (CDI) is the most common cause of infectious colitis in the USA, with a fatality rate that increased from 1.2% in 2000 to 2.2% in 2004.¹ Risk factors for CDI include age, prior hospitalizations, prior antibiotic use, proton pump inhibitor use,² inflammatory bowel diseases (IBD)³; and more recently, there is also data to suggest that patients with lower vitamin D levels have a more aggressive CDI course.⁴

The importance of vitamin D in diseases beyond calcium homeostasis and bone health is becoming more apparent. Vitamin D has been found to have an antimicrobial effect, aiding the macrophage suppression of mycobacterial growth, in in vitro experiments.⁵ This

inhibition is believed to be mediated through the induction of cathelicidin, an antimicrobial peptide.^{6,7} Recent in vitro and in vivo experiments in mice demonstrate that exogenous administration of cathelicidin could suppress intestinal damage due to CDI.⁸ In epidemiological studies of patients who are critically ill,

¹Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

²Center for Clinical Management Research, US Department of Veteran's Affairs, Ann Arbor, MI, USA

Corresponding author:

Shail M Govani, 3912 Taubman Center, 1500 E Medical Center Drive, SPC 5362, Ann Arbor, MI 48109-5362.

Email: shailg@umich.edu

vitamin D deficiency is found to be a risk factor for mortality.⁹ Additionally, studies of vitamin D and CDI suggest that patients with vitamin D deficiency have longer hospitalizations and increased healthcare-associated costs.⁴

Sunlight, in the form of ultraviolet (UV) radiation, provides a major source of vitamin D; UV-B radiation converts 7-dehydrocholesterol into pre-vitamin D, which is later converted to vitamin D3.¹⁰ The broad importance of vitamin D in gut immunity is highlighted by the finding of an inverse relationship between vitamin D levels and the risk of diverticulitis.¹¹ We aimed to study whether UV light exposure is related to CDI inpatient mortality, using the US National Inpatient Sample (NIS) data from 2004 to 2011. We hypothesized that patients in areas with more UV light exposure will have lower mortality, adjusting for age, gender and other comorbidities.

Methods

The NIS is a de-identified dataset of a 20% stratified sample of inpatient hospitalizations. For this analysis, the 2004–2011 NIS datasets were used for analysis. Each hospitalization is characterized as a single record, with discharge diagnoses, procedure codes and socioeconomic data. The data abstraction process to obtain UV exposure is described in detail, in a prior publication.¹² Briefly, annual UV light exposure was obtained from published maps by the US Environmental Protection Agency (EPA).¹³ These maps showed the average UV index for each month, from 2006–2010; the map was divided into 144 cells, which were then matched to the corresponding 3-digit zip code (the first three digits of the 5-digit zip code, designating one area within a state). We calculated the average annual values per 3-digit zip code. These values were then validated, by comparing the results to the 12-year average for 500 cities around the country. The level of UV exposure was characterized by measurement of the UV index. The UV index is a linear-scale prediction of the ground level UV radiation, factoring in elevation, cloud cover, ozone levels developed by the US EPA and the US National Oceanic and Atmospheric Association (NOAA).¹⁴ This value ranges from 0 to greater than 11. As the zip-code level data is only available for the hospital location, and not for the patient's home; and that data is missing from 31.4% of hospitalizations, we elected to calculate a state UV index average to apply to each hospitalization. We calculated a Charlson-Deyo comorbidity score for each hospitalization, in order to factor in the effects of comorbidities on the risk of mortality.¹⁵ We analyzed all hospitalizations

where CDI was a primary or a secondary diagnosis (based on ICD9-CM code 008.45), as studies show that primary ICD-9CM codes are valid and reliable in large administrative datasets.^{16,17} In order to compare hospitalization numbers across the country, the UV index was categorized into approximately equal population tertiles. We used US Census data from 2010 to determine state populations. Ulcerative colitis (UC) was classified as a diagnosis of ICD-9CM code 556.X and Crohn's disease was classified as a diagnosis of ICD-9CM code 555.X. The ICD9-CM diagnosis codes used for infection are located in Supplementary Table 1.

Statistical analysis

We performed the statistical analysis using SAS 9.3 (Cary, NC, USA). The appropriate PROC SURVEY commands were used, in order to generate national estimates. The baseline characteristics of the population were compared with the Rao-Scott chi-square test for categorical variables or the student's *t*-test for numerical variables. We performed both univariate and multivariate logistic regression analysis, using PROC SURVEYLOGISTIC, to determine individual effects as odds ratios (ORs). All major clinical characteristics and demographic characteristics were combined in the multivariable model.

Results

In the US from 2004 to 2011, there were an estimated 2.61 million (SD 61,110) hospitalizations with a primary or secondary diagnosis of CDI. The overall mortality rate for this group was 9.0%. Of these hospitalizations, 790,854 were for primary diagnoses of CDI. The mortality rate was 11.3% among those with a secondary diagnosis, versus 3.5% among those with a primary diagnosis. Patients who died were more likely to be older (75.1 years versus 67.4 years, $p < 0.001$) and less likely to be female (54.2% versus 58.3%, $p < 0.001$). Additionally, there were differences in the insurance type and household income between those whom survived and those whom passed away (Table 1). The discharge quarter indicated that a larger proportion of the deaths occurred in the first one-half of the year, compared to later months ($p < 0.001$).

The average national population-adjusted UV Index was 4.59 (2010 US Census data). On the state level, the average yearly UV Index ranged from 0.66 units in AK, to 9.3 units in HI (Figure 1(a)). The average UV exposure among hospitalizations that led to mortality was lower (4.4 UV Index units versus 4.5, $p = 0.009$).

Table 1. Baseline characteristics

	Survived <i>C. difficile</i> infection (<i>n</i> = 2,370,320)	Deceased from <i>C. difficile</i> infection (<i>n</i> = 233,118)
Age (years)	67.4 (± 0.2)	75.1 (± 0.2)
Female (%)	58.3 (± 0.2)	54.2 (± 0.3)
Race (%)		
Caucasian	75.6 (± 0.6)	75.3 (± 0.7)
African-American	11.7 (± 0.4)	11.4 (± 0.5)
Hispanic	7.8 (± 0.4)	7.7 (± 0.4)
Other	4.8 (± 0.2)	5.6 (± 0.3)
Payer Information (%)		
Medicare	67.8 (± 0.4)	78.2 (± 0.4)
Medicaid	8.9 (± 0.2)	6.1 (± 0.2)
Private (including HMO)	19.2 (± 0.3)	12.6 (± 0.3)
Other	4.1 (± 0.1)	3.1 (± 0.1)
Median household income		
Quartiles for patient's Zip (%)		
1–38,999	25.5 (± 0.6)	25.0 (± 0.7)
39,000–47,999	24.8 (± 0.5)	24.1 (± 0.6)
48,000–62,999	25.0 (± 0.4)	24.6 (± 0.5)
63,000+	24.6 (± 0.8)	26.3 (± 1.0)
Discharge quarter (%)		
January–March	25.7 (± 0.1)	27.7 (± 0.2)
April–June	25.9 (± 0.1)	25.9 (± 0.2)
July–September	24.3 (± 0.1)	22.6 (± 0.2)
October–December	24.1 (± 0.1)	23.7 (± 0.2)
Length of Stay (days)	12.3 (± 0.1)	16.7 (± 0.3)
Total charges (\$US)	69,015.0 (± 1324.1)	126,774.9 (± 3207.3)
UC (%)	1.6 (± 0.03)	2.4 (± 0.09)
Crohn's disease (%)	1.0 (± 0.03)	0.3 (± 0.03)
Co-existing bacterial infection (%)	29.8 (± 0.2)	66.7 (± 0.4)
Charlson-Deyo comorbidity score	1.9 (± 0.01)	2.4 (± 0.02)
Mean UV Index (units)	4.5 (± 0.03)	4.4 (± 0.03)

C. difficile: *Clostridium difficile* bacteria; HMO: health maintenance organization; UC: ulcerative colitis; UV: ultraviolet light ; Zip: US postal Zip code for locations throughout the country.

Comparing the proportions of hospitalizations, we found there was a significant difference in the percentage of hospitalizations across UV Index tertiles for CDI, as compared to all hospitalizations ($p < 0.001$). The largest proportion of hospitalizations was in the lowest tertile of UV exposure (Figure 1(b)).

In a univariate analysis of mortality among those with CDI, the factors of age, gender, insurance status, as well as coexisting UC, infection and Charlson-Deyo comorbidity index were all associated with mortality (Table 2). The UV Index was inversely related to inpatient mortality, with a 3% reduction in the odds of death per 1-unit increase in UV Index among patients with a primary or secondary diagnosis of CDI. For comparison, among those with only a primary

diagnosis of CDI, the OR of inpatient mortality for each unit increase in UV Index was 0.91 (95% CI 0.88–0.95; $p < 0.001$). The odds of inpatient mortality were higher for hospitalizations occurring from January to March, compared to the last 3 months of the year. This is notable, as the nadir of vitamin D serum levels occurs at the end of winter in the USA.

In order to control for important comorbidities and age that are associated with mortality, a multivariate model with the UV Index and these covariates was constructed (Table 3). Accounting for the Charlson-Deyo comorbidity score, age, race, the patient's inflammatory bowel diseases, quarter of discharge from hospitalization and co-existing bacterial infections, we found that the mean annual UV Index remains a protective factor

Figure 1. Color-coded geographic map of the USA demonstrates the average UV Index exposure per state, categorized by approximately equal population tertiles. (a) The highest area of UV light exposure in the continental US is centered in the Southwest.¹⁸ (b) The percentage breakdown of primary or secondary CDI diagnoses over the UV Index tertiles was statistically different from the breakdown of hospitalizations without a CDI diagnosis.

Source: Govani SM, Higgins PDR, Stidham RW, et al. Increased Ultraviolet Light Exposure is Associated with Reduced Risk of Inpatient Surgery Among Patients with Crohn's Disease. *J Crohn's Colitis*. 2015; 9: 77–81.

for inpatient CDI mortality. For each 5-unit increase in the annual UV Index, the OR of inpatient mortality (adjusting for these other important covariates) is 0.74, resulting in a 26% decrease in the odds of death.

We then tested this model in a series of sensitivity analyses. As certain states (CA and CO) have high UV standard deviations (~ 0.5), we performed a sensitivity analysis that excluded hospitalizations in those states. This analysis returned essentially the same results for UV Index effect on inpatient mortality in the multivariable model (OR = 0.93; 95% CI 0.91–0.95). With the annual average UV Index for 3-digit zip codes, we were able to perform an analysis on the subset of visits with more localized zip code UV exposure data. This analysis once again showed a protective effect (Table 4).

Finally, we repeated our analysis excluding the state of HI, due to the fact that the average annual UV Index is much higher and the number of CDI-related deaths in HI was quite low. This analysis again showed a

protective effect in a multivariate analysis (OR = 0.94; 95% CI 0.92–0.96). When only hospitalizations with a primary diagnosis of CDI were considered in our analysis, UV Index again demonstrated a protective association with inpatient mortality (OR = 0.92; 95% CI 0.88–0.96; $p < 0.001$). In contrast to the association between UV exposure and CDI mortality, an examination of all hospitalizations during the 8-year period found that UV Index was not protective of all-cause inpatient mortality (OR = 1.00; 95% CI 0.98–1.02; $p = 1.00$).

Discussion

In this ecological study of NIS data from 2004–2011, we found an inverse relationship between inpatient mortality and the average yearly UV Index exposure in patients with a diagnosis of CDI. Based on the estimates from our logistic model, a patient from AZ is

Table 2. Univariate ORs of inpatient mortality in patients with CDI

Predictor	OR of mortality	95% CI	p value
Age (per year)	1.03	1.026–1.028	<0.001
Race			
Caucasian	1	Reference	<0.001
African-American	0.98	0.93–1.02	
Hispanic	0.99	0.94–1.05	
Other	1.17	1.10–1.24	
Female vs. male gender	0.85	0.83–0.86	<0.001
Payer			
Medicare	1	Reference	<0.001
Medicaid	0.60	0.57–0.64	
Private	0.57	0.55–0.59	
Other	0.65	0.61–0.70	
Median household income quartiles for patient's zip			
1–38,999	1	Reference	<0.001
39,000–47,999	0.99	0.96–1.03	
48,000–62,999	1.00	0.97–1.04	
63,000+	1.09	1.04–1.14	
UC	1.50	1.39–1.61	<0.001
Crohn's disease	0.32	0.27–0.38	<0.001
Co-existing bacterial infection	4.73	4.59–4.87	<0.001
Charlson-Deyo (per 1 unit)	1.15	1.14–1.15	<0.001
Mean UV (per 1 unit)	0.97	0.95–0.99	0.008
Discharge quarter			
January-March	1.10	1.07–1.13	<0.001
April-June	1.02	0.99–1.05	
July-September	0.95	0.92–0.98	
October-December	1	Reference	

CDI: *Clostridium difficile* infection; OR: odds ratio; UC: ulcerative colitis; UV: ultraviolet light; Zip: postal US Zip code.

Table 3. Multivariate ORs of inpatient mortality among patients with CDI

Predictor	OR	95% CI	p value
Age (per year)	1.03	1.03–1.03	<0.001
Race			<0.001
Caucasian	1	Reference	
African-American	1.01	0.96–1.05	
Hispanic	1.11	1.05–1.17	
Other	1.15	1.08–1.22	
Female vs. male	0.88	0.86–0.90	<0.001
UC	1.90	1.76–2.05	<0.001
Crohn's disease	0.67	0.56–0.80	<0.001
Co-existing bacterial infection	4.80	4.64–4.95	<0.001
Charlson-Deyo (per 1 unit)	1.15	1.14–1.16	<0.001
Mean UV Index (per 1 unit)	0.94	0.92–0.96	<0.001
Discharge quarter			
January-March	1	Reference	<0.001
April-June	0.93	0.90–0.95	
July-September	0.86	0.84–0.89	
October-December	0.90	0.88–0.93	

CDI: *Clostridium difficile* infection; OR: odds ratio; UC: ulcerative colitis.

Table 4. Sensitivity analysis: Multivariate Model^a of Mortality due to CDI, with various UV exposure variables

Predictor	OR	95% CI	p value
Average Annual UV Index (state)	0.94	0.92–0.96	<0.001
Average Annual UV Index (hospital Zip code)	0.93	0.91–0.95	<0.001
Average Annual UV Index (state), excluding states with high SDs	0.93	0.91–0.95	<0.001
Average Annual UV Index (State), excluding HI	0.94	0.92–0.96	<0.001

^aMultivariate models control for age, gender, race, UC, Crohn's disease, concomitant infection, discharge quarter and Charlson-Deyo Index.

CDI: *Clostridium difficile* infection; SD: standard deviation; UC: ulcerative colitis; UV: ultraviolet light.

16% less likely to die in the hospital from CDI than a patient of the same age, gender and other comorbidities in MI.

While there are a number of studies showing an association between latitude and the incidence of inflammatory bowel diseases,^{19,20} this is the first study that we know of that has examined the association between UV exposure and hospitalizations for CDI. The strengths of this study include the size of the database, which represents more than 200 million hospitalizations in the US over an 8-year period and includes extensive discharge diagnosis data, demographics and comorbidity data. The significance of discharge quarter in the multivariable model is further evidence that the protective effect of UV light may be mediated through vitamin D. A recent study of the season variation of vitamin D revealed a peak serum vitamin D in August and a nadir in February.²¹ Our study found that the last quarter of the year had lower inpatient mortality, which could be due to the delayed response of vitamin D levels to summer UV exposure.

The study's major limitations included the fact that it was based on administrative data, which may have imperfect discharge coding, and that the associations seen here could possibly be due to another unknown factor. We focused our analysis on hospitalizations with primary or secondary diagnoses of CDI, in order to capture patients in whom CDI was the major diagnosis (and therefore, a main contributor to mortality). We note that the mortality rate among patients with a primary diagnosis of CDI is 3.5%, which is lower than the mortality rate among those with a secondary diagnosis (11.3%). While we studied the association between UV and mortality among patients with CDI, we do not have a method to determine whether the cause of death was due to CDI; however, the

association between UV exposure and inpatient mortality was stronger for patients with only a primary diagnosis of CDI. Our data cannot account for migratory patterns of Americans or other confounding exposures that may be more likely to occur in the US South/Southwest and could be protective against CDI mortality. Additionally, the dataset did not allow for adjustment for other important predictors of CDI, such as serum albumin, proton pump inhibitor use or white blood cell count.

While we hypothesize that the protective effect of UV light on CDI mortality is mediated through increased levels of vitamin D, it is possible that sunlight and/or warmth itself may have some protective effect. It is also possible that an indirectly associated factor, i.e. use of sunscreen, could be protective rather than UV light or vitamin D. In animal models of multiple sclerosis, an autoimmune disease with similar geographic associations as CD, it was shown that UV light has a beneficial effect, independent of vitamin D levels.^{22,23}

Future studies will need to be done in other large datasets, to see if the relationship between CDI mortality and UV light persists. With the increasing incidence of CDI and the high prevalence of vitamin D deficiency in the elderly population, further research is needed to confirm this association and to determine whether interventions such as vitamin D supplementation can change CDI outcomes.

Funding statement

This work was supported by the Inflammatory Bowel Disease Working Group through an unrestricted educational grant by UCB Inc (GI Fellows Research Award to SMG) and the US Veterans' Administration (VA HSR&D CDA-2 Career Development Award number 1IK2HX000775, to AKS).

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

We would like to acknowledge Scott Montain, from the US Army Research Institute of Environmental Medicine, for sharing his UV data with us.

References

1. Zilberberg MD, Shorr AF and Kollef MH. Increase in adult *Clostridium difficile* -related hospitalizations and case-fatality rate, United States, 2000–2005. *Emerg Infect Dis* 2008; 14: 929.
2. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for *Clostridium difficile* -associated diarrhea in hospitalized patients. *Am J Gastroenterol* 2008; 103: 2308–2313.

3. Ananthakrishnan AN. *Clostridium difficile* infection: Epidemiology, risk factors and management. *Nat Rev Gastroenterol Hepatol* 2011; 8: 17–26.
4. Youssef D, Bailey B, El Abbassi A, et al. Healthcare costs of *Staphylococcus aureus* and *Clostridium difficile* infections in Veterans: Role of vitamin D deficiency. *Epidemiol Infect* 2010; 138: 1322–1327.
5. Crowle AJ, Ross EJ and May MH. Inhibition by 1,25(OH)₂-vitamin D₃ of the multiplication of virulent tubercle bacilli in cultured human macrophages. *Infect Immun* 1987; 55: 2945–2950.
6. Liu PT, Stenger S, Tang DH, et al. Cutting edge: Vitamin D-mediated human antimicrobial activity against *Mycobacterium tuberculosis* is dependent on the induction of cathelicidin. *J Immunol* 2007; 179: 2060–2063.
7. Guo C, Sinnott B, Niu B, et al. Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. *Mol Nutr Food Res* 2013; 58: 528–536.
8. Hing TC, Ho S, Shih DQ, et al. The antimicrobial peptide cathelicidin modulates *Clostridium difficile* -associated colitis and toxin A-mediated enteritis in mice. *Gut* 2013; 62: 1295–1305.
9. Venkatram S, Chilimuri S, Adrish M, et al. Vitamin D deficiency is associated with mortality in the medical intensive care unit. *Critical Care* 2011; 15: R292.
10. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007; 357: 266–281.
11. Maguire LH, Song M, Strate LE, et al. Higher serum levels of vitamin D are associated with reduced risk of diverticulitis. *Clin Gastroenterol Hepatol* 2013; 11: 1631–1635.
12. Montain SJ, McGraw SM, Ely MR, et al. A retrospective cohort study on the influence of UV index and race/ethnicity on risk of stress and lower limb fractures. *BMC Musculoskelet Disord* 2013; 14: 135–143.
13. US Environmental Protection Agency. Monthly Average UV Index, www2.epa.gov/sunwise/monthly-average-uv-index#tab-1 (2014, accessed 11 May 2014).
14. US Environmental Protection Agency. UV Index, www2.epa.gov/sunwise/uv-index (2014, accessed 29 Jan 2014).
15. Deyo RA, Cherkin DC and Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992; 45: 613–619.
16. Scheurer DB, Hicks LS, Cook EF, et al. Accuracy of ICD-9 coding for *Clostridium difficile* infections: A retrospective cohort. *Epidemiol Infect* 2007; 135: 1010–1013.
17. Tirschwell DL and Longstreth WT. Validating administrative data in stroke research. *Stroke* 2002; 33: 2465–2470.
18. Govani SM, Higgins PDR, Stidham RW, et al. Increased ultraviolet light exposure is associated with reduced risk of inpatient surgery among patients with Crohn's disease. *J Crohn's Colitis* 2015; 9: 77–81.
19. Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. *Gut* 2012; 61: 1686–1692.
20. Nerich V, Monnet E, Etienne A, et al. Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data. *Inflam Bowel Dis* 2006; 12: 218–226.
21. Kasahara AK, Singh RJ and Noymer A. Vitamin D (25OHD) serum seasonality in the United States. *PLoS One* 2013; 8: e65785.
22. Becklund BR, Severson KS, Vang SV, et al. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. *Proc Nat Acad Sci* 2010; 107: 6418–6423.
23. Wang Y, Marling SJ, McKnight SM, et al. Suppression of experimental autoimmune encephalomyelitis by 300–315 nm ultraviolet light. *Arch Biochem Biophys* 2013; 536: 81–86.